ArticleAntioxidants (Basel, Switzerland)2021

The Damaging Outcome of the POLAR Phase III Trials Was Due to Avoidable Time-Dependent Redox Interaction between Oxaliplatin and PledOx.

Jan Olof G Karlsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.